Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Publication date: Available online 16 October 2018Source: European UrologyAuthor(s): Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, Pasquale Rescigno, Wei Yuan, Suzanne Carreira, Maialen Barrero, Antonella Petremolo, Susana Miranda, Ruth Riisnaes, Daniel Nava Rodrigues, Bora Gurel, Semini Sumanasuriya, Alec Paschalis, Adam Sharp, Joaquin Mateo, Nina Tunariu, Arul M. Chinnaiyan, Colin C. Pritchard, Kevin KellyAbstractPlatinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA ...
Source: European Urology - October 17, 2018 Category: Urology & Nephrology Source Type: research

Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641–2
Publication date: Available online 16 October 2018Source: European UrologyAuthor(s): Francesco Montorsi, Giorgio Gandaglia (Source: European Urology)
Source: European Urology - October 17, 2018 Category: Urology & Nephrology Source Type: research

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial
ConclusionsExtended LND failed to show a significant advantage over limited LND in RFS, CSS, and OS. A larger trial is required to determine whether extended compared with limited LND leads to a small, but clinically relevant, survival difference (ClinicalTrials.gov NCT01215071).Patient summaryIn this study, we investigated the outcome in bladder cancer patients undergoing cystectomy based on the anatomic extent of lymph node resection. We found that extended removal of lymph nodes did not reduce the rate of tumor recurrence in the expected range. (Source: European Urology)
Source: European Urology - October 17, 2018 Category: Urology & Nephrology Source Type: research

Can We Prevent Bladder Cancer Recurrences?
Publication date: Available online 15 October 2018Source: European UrologyAuthor(s): John L. Gore, Jonathan L. Wright (Source: European Urology)
Source: European Urology - October 17, 2018 Category: Urology & Nephrology Source Type: research

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
Publication date: Available online 15 October 2018Source: European UrologyAuthor(s): Emmanuel S. Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, Harsimar Kaur, Eugene Shenderov, Drew M. Pardoll, Tamara L. LotanAbstractMismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown. We conducted a retrospective study to explore disease characteristics and treatment outcomes of men with metastatic prostate cancer harboring germline and/or somatic MMR mutations detected using clinical-grade genomic assays. Thirteen patients with a deleterious MMR gen...
Source: European Urology - October 17, 2018 Category: Urology & Nephrology Source Type: research

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
ConclusionsThe treatment landscape for mccRCC has evolved since the introduction of VEGF inhibitors. Combination therapies involving checkpoint inhibitors could be the next standard of care.Patient summaryWith the expanding role of immune checkpoint inhibitors in metastatic renal cell carcinoma, the treatment paradigm has shifted to include combination therapy in the untreated setting. As the field advances, the bar has been raised in evaluating ongoing combination strategies. (Source: European Urology)
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes
Publication date: Available online 13 October 2018Source: European UrologyAuthor(s): Francesco Greco, Riccardo Autorino, Vincenzo Altieri, Steven Campbell, Vincenzo Ficarra, Inderbir Gill, Alexander Kutikov, Alex Mottrie, Vincenzo Mirone, Hendrik van PoppelAbstractContextThe optimal ischemia technique at partial nephrectomy (PN) for renal masses is yet to be determined.ObjectiveTo summarize and analyze the current evidence about surgical, oncological, and functional outcomes after different ischemia techniques (cold, warm, and zero ischemia) at PN.Evidence acquisitionA computerized systematic literature search was performe...
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.05.005
Publication date: Available online 14 October 2018Source: European UrologyAuthor(s): So-Ryoung Lee, Byoung-Won Park, Jae Heon Kim (Source: European Urology)
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
Publication date: Available online 14 October 2018Source: European UrologyAuthor(s): Andrew J. Vickers, Hans Lilja, Melissa Assel (Source: European Urology)
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

Innovations in Statistical Review at European Urology
Publication date: Available online 14 October 2018Source: European UrologyAuthor(s): Melissa Assel, Daniel D. Sjoberg, James W.F. Catto, Andrew J. Vickers (Source: European Urology)
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI
Publication date: Available online 14 October 2018Source: European UrologyAuthor(s): Veeru Kasivisvanathan, Alessandro Ambrosi, Francesco Giganti, Edwin Chau, Alex Kirkham, Shonit Punwani, Clare Allen, Mark Emberton, Caroline M. Moore (Source: European Urology)
Source: European Urology - October 15, 2018 Category: Urology & Nephrology Source Type: research

Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
Publication date: Available online 12 October 2018Source: European UrologyAuthor(s): Kathryn L. Penney, Massimo Loda, Meir J. Stampfer (Source: European Urology)
Source: European Urology - October 13, 2018 Category: Urology & Nephrology Source Type: research

askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men
ConclusionsUsing clinical registry data and machine learning methods, we created a web-based platform for patients that generates accurate predictions for most CaP treatments.Patient summaryWe have developed and tested a tool to help men newly diagnosed with prostate cancer to view predicted treatment decisions based on similar patients from our registry. We have made this tool available online for patients to use. (Source: European Urology)
Source: European Urology - October 12, 2018 Category: Urology & Nephrology Source Type: research

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR)
This study illustrates that increasing the imaging frequency during follow-up, even to double the number of follow-up imaging procedures recommended by the European Association of Urology guidelines, does not translate into improved survival for those with recurrence. (Source: European Urology)
Source: European Urology - October 12, 2018 Category: Urology & Nephrology Source Type: research

Treatment of Varicocele in Children and Adolescents: A Systematic Review and Meta-analysis from the European Association of Urology/European Society for Paediatric Urology Guidelines Panel
ConclusionsModerate evidence exists on the benefits of varicocele treatment in children and adolescents in terms of testicular volume and sperm concentration. Current evidence does not demonstrate superiority of any of the surgical/interventional techniques regarding treatment success. Long-term outcomes including paternity and fertility still remain unknown.Patient summaryIn this paper, we review benefits and harms of varicocele treatment in children and adolescents. We found moderate evidence that varicocele treatment results in improvement of testicular volume and sperm concentration. Lymphatic sparing surgery decreases...
Source: European Urology - October 12, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): (Source: European Urology)
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

The Platinum Hall of Fame
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): (Source: European Urology)
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Contents
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): (Source: European Urology)
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): Rafael Sanchez-Salas, Jean de la Rosette, Thomas J. Polascik, Arie Carneiro, Arjun Sivaraman, Xavier Cathelineau, Jochen Walz (Source: European Urology)
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): Jennifer A. Sinnott, Katherine Brumberg, Kathryn M. Wilson, Ericka M. Ebot, Edward L. Giovannucci, Lorelei A. Mucci, Jennifer R. RiderAbstractIn a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n = 157 tumor tissue, n = 8...
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): Maxine Sun, Lorenzo Marconi, Tim Eisen, Bernard Escudier, Rachel H. Giles, Naomi B. Haas, Lauren C. Harshman, David I. Quinn, James Larkin, Sumanta K. Pal, Thomas Powles, Christopher W. Ryan, Cora N. Sternberg, Robert Uzzo, Toni K. Choueiri, Axel BexAbstractContextContradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC).ObjectiveTo systematically evaluate the current evidence regarding the therapeutic benefi...
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Congress Calendar
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): (Source: European Urology)
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses
Publication date: November 2018Source: European Urology, Volume 74, Issue 5Author(s): Francesco Porpiglia, Cristian Fiori, Enrico Checcucci, Daniele Amparore, Riccardo BertoloAbstractBackgroundAvailable technologies could avoid global ischemia for the removal of a renal tumor.ObjectiveTo present hyperaccuracy three-dimensional (HA3D) reconstruction during robot-assisted partial nephrectomy (RAPN) and compare its efficacy in sponsoring successful selective clamping of renal arterial branches during RAPN.Design, setting, and participantsPatients undergoing RAPN (January 2016–July 2017) for renal mass PADUA score ≥10...
Source: European Urology - October 10, 2018 Category: Urology & Nephrology Source Type: research

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
ConclusionsMutation status of BRCA1/2 and ATM is associated with GR among men undergoing AS.Patient summaryMen on active surveillance with inherited mutations in BRCA1/2 and ATM are more likely to harbor aggressive prostate cancer. (Source: European Urology)
Source: European Urology - October 9, 2018 Category: Urology & Nephrology Source Type: research

Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641–2
Publication date: Available online 6 October 2018Source: European UrologyAuthor(s): Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, Anne Sörenby, Fredrik Liedberg (Source: European Urology)
Source: European Urology - October 7, 2018 Category: Urology & Nephrology Source Type: research

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
In this study, we evaluated the prognostic value of BCG unresponsive designation (i.e. recurrence after induction plus at least 1 maintenance course of BCG) by comparing the oncologic outcomes of these patients with those recurring after induction BCG alone. We confirm that appropriately defined, BCG-unresponsive patients are more likely to require salvage radical cystectomy (54.5% vs 17.9%, p = 0.002). Moreover, those opting for second-line bladder-sparing therapies are less likely to remain free of tumor recurrence (23% vs 69.2%, p = 0.003). On multivariate analysis, BCG-unresponsive disease independe...
Source: European Urology - October 7, 2018 Category: Urology & Nephrology Source Type: research

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis
Publication date: Available online 6 October 2018Source: European UrologyAuthor(s): Nicola Fossati, Nazareno Suardi, Giorgio Gandaglia, Carlo A. Bravi, Matteo Soligo, R. Jeffrey Karnes, Shahrokh Shariat, Antonino Battaglia, Wouter Everaerts, Steven Joniau, Hendrik Van Poppel, Nieroshan Rajarubendra, Inderbir S. Gill, Alessandro Larcher, Alexander Mottrie, Maximilian Schmautz, Axel Heidenreich, Almut Kalz, Daniar Osmonov, Klaus-Peter JuenemannAbstractBackgroundSalvage lymph node dissection (SLND) represents a possible treatment option for prostate cancer patients affected by nodal recurrence after local treatment. However, ...
Source: European Urology - October 7, 2018 Category: Urology & Nephrology Source Type: research

A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG
ConclusionsOur study confirms that vigorous physical activity is associated with lower risk of advanced and lethal PCa and provides novel evidence for a lower risk of TMPRSS2:ERG-positive disease.Patient summaryThe identification of modifiable lifestyle factors for prevention of clinically important prostate cancer (PCa) is needed. In this report, we compared risk of PCa in men with different levels of physical activity. Men with higher vigorous activity had a lower risk of developing advanced and lethal PCa and PCa with the common TMPRSS2:ERG gene fusion. (Source: European Urology)
Source: European Urology - October 7, 2018 Category: Urology & Nephrology Source Type: research

Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma
Publication date: Available online 24 September 2018Source: European UrologyAuthor(s): Boris Gershman, R. Houston Thompson, Stephen A. Boorjian, Christine M. Lohse, Brian A. Costello, John C. Cheville, Bradley C. LeibovichAbstractBackgroundNephron-sparing surgery is the preferred surgical management of cT1 renal masses, but observational and randomized data conflict regarding a survival benefit.ObjectiveTo examine the associations of radical nephrectomy (RN) versus partial nephrectomy (PN) with oncologic and nononcologic outcomes.Design, setting, and participantsA total of 2459 adults were treated with RN or PN between 199...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed
Publication date: Available online 24 September 2018Source: European UrologyAuthor(s): Pontus Eriksson, Gottfrid Sjödahl, Fredrik Liedberg (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?
Publication date: Available online 24 September 2018Source: European UrologyAuthor(s): Ashwin Shinde, Richard Li, Scott Glaser, Arya Amini (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

“Ride the Green Light”: Indocyanine Green–marked Off-clamp Robotic Partial Nephrectomy for Totally Endophytic Renal Masses
ConclusionsWe described a novel technique to simplify challenging RAPN based on ICG superselective transarterial tumor marking. Key benefits include quick intraoperative identification of the mass with improved visualization and real-time control of resection margins.Patient summaryRobot-assisted partial nephrectomy (RAPN) for totally endophytic renal masses is a technically demanding surgical procedure, sometimes requiring radical nephrectomy. This novel technique significantly simplified surgical complexity in our Institution. Further studies with larger cohorts are warranted to confirm whether this technique provides re...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294–306
Publication date: Available online 24 September 2018Source: European UrologyAuthor(s): Jeremy Y.C. Teoh, Thomas R.W. Herrmann, Marek Babjuk (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
ConclusionsThe current RCT comparing ADT to ADT with EBRT to the prostate in patients with primary bone mPCa did not show a significant difference in overall survival, although the CI cannot exclude a substantial survival benefit. Further research is needed to confirm our findings.Patient summaryThis study investigated the effect of adding radiation therapy to the prostate to hormonal therapy in prostate cancer patients with metastasis to the bone at diagnosis. In our patient group, additional radiotherapy did not improve overall survival. Further research is needed to confirm our findings.Twitter summaryAdding radiotherap...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
In this report, we investigated molecular diversity among different areas from the same tumor in patients with bladder cancer. We found that different areas from the same tumor are often molecularly different. We conclude that this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples. (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
ConclusionsEvidence is emerging regarding gene-environment interactions, particularly for tobacco and occupational exposures. In some populations, incidence rates are declining, which may reflect a decrease in smoking. Standardisation of reporting may help improve epidemiologic evaluation of risk.Patient summaryBladder cancer is common worldwide, and the main risk factors are tobacco smoking and exposure to certain chemicals in the working and general environments. There is ongoing research to identify and reduce risk factors, as well as to understand the impact of genetics on bladder cancer risk. (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52
Publication date: Available online 26 September 2018Source: European UrologyAuthor(s): Tom J.H. Arends, J. Alfred Witjes (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Is Androgen Deprivation Therapy “Another Deficient Therapy” for Gleason Score 9-10 Prostate Cancer?
Publication date: Available online 26 September 2018Source: European UrologyAuthor(s): Matthew P. Deek, Ryan M. Phillips, Michael Haffner, Phuoc T. Tran (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Harnessing New Media Tools in Patient Information
Publication date: Available online 27 September 2018Source: European UrologyAuthor(s): Thorsten Bach, Mark Behrendt, Yiloren Tanidir, Philip Cornford, Yinghao Sun, Hendrik Van Poppel (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525–36: Blood Loss in Robot-assisted Radical Cystectomy: An Important Patient Benefit
Publication date: Available online 27 September 2018Source: European UrologyAuthor(s): Sandaruwani Abeysiri, Toby Richards (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement
Publication date: Available online 27 September 2018Source: European UrologyAuthor(s): Rebecca E. Graff, Linda Kachuri, John S. Witte (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
ConclusionsLongitudinal integration of individual patient parameters may ultimately lead to personalized and dynamic immunotherapy, to adjust to the Darwinian forces that drive tumor evolution. Incorporating multiparameter biomarkers into quantitative predictive models will be a key challenge to integrate the immunogram into daily clinical practice.Patient summaryHere, we propose the urothelial cancer immunogram, a novel way of describing important immunological characteristics of urothelial cancer patients and their tumors. Seven characteristics determine the chance of having an immunological tumor response. Using this im...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up
Publication date: Available online 28 September 2018Source: European UrologyAuthor(s): Masakatsu Oishi, Inderbir S. Gill, Akbar N. Ashrafi, Michael Lin-Brande, Nima Nassiri, Toshitaka Shin, Alfredo Bove, Giovanni E. Cacciamani, Osamu Ukimura, Duke K. Bahn, Andre Luis de Castro AbreuAbstractWe retrospectively evaluated complications and functional and oncologic outcomes of 94 consecutive men who underwent primary whole-gland cryoablation for localized prostate cancer (PCa) from 2002 to 2012. Kaplan-Meier and multivariable Cox regression analyses were performed using a landmark starting at 6 mo of follow-up. In total, 75% pa...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Lessons Learned from the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101
Publication date: Available online 28 September 2018Source: European UrologyAuthor(s): Zachary Klaassen, Rashid K. Sayyid, Christopher J.D. Wallis (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?
Publication date: Available online 28 September 2018Source: European UrologyAuthor(s): Nicholas J. Vogelzang (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
ConclusionsDFS was similar between RITE and control. RITE may be a second-line therapy for non-CIS recurrence following BCG failure; however, confirmatory trials are needed. RITE patients with CIS with/without papillary had lower DFS than control. HYMN highlights the importance of the control arm when evaluating novel therapies.Patient summaryThis study did not show a difference in bladder cancer outcomes between microwave-heated chemotherapy and standard of care treatment. Papillary bladder lesions may benefit from microwave-heated chemotherapy treatment; however, more research is needed. Both treatments are similarly wel...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Towards Next-generation Urine-based Prostate Cancer Risk Stratification
Publication date: Available online 28 September 2018Source: European UrologyAuthor(s): Tobias Nordström, Johan Lindberg, Martin Eklund (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
ConclusionsBOXIT did not show that celecoxib reduces the risk of recurrence in intermediate- or high-risk NMIBC, although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib.Patient summaryCelecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non–muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib. (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer
ConclusionsIn contrast to the clearly demonstrated survival benefits of long-term adjuvant ADT when used with EBRT, its role after prostatectomy remains unclear especially in pN0 patients. Adding docetaxel to EBRT-ADT improves relapse-free survival, with immature results on overall survival. Novel androgen receptor pathway inhibitors are currently being tested in the neoadjuvant and adjuvant setting.Patient summaryTreatment of high-risk prostate cancer is based on a multimodality approach that includes systemic treatments. The best treatment or therapy combination remains to be defined. (Source: European Urology)
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
ConclusionsPatients with secondary MIBC treated with NAC had worse clinical outcomes than similarly treated patients with primary MIBC. ERCC2 mutations predicted to result in increased cisplatin sensitivity were enriched in primary versus secondary MIBC. Prospective validation is still needed, but given the lack of clinical benefit with cisplatin-based NAC in patients with secondary MIBC, upfront RC or enrollment in clinical trials should be considered.Patient summaryA retrospective cohort study of patients with “primary” and “secondary” muscle-invasive bladder cancer (MIBC) treated with chemotherap...
Source: European Urology - October 5, 2018 Category: Urology & Nephrology Source Type: research